| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.JALZ.2010.03.008 |
| P8608 | Fatcat ID | release_uemiozd7pfai7dxei2iclp34ge |
| P932 | PMC publication ID | 2867838 |
| P698 | PubMed publication ID | 20451871 |
| P5875 | ResearchGate publication ID | 44581957 |
| P50 | author | Alzheimer's Disease Neuroimaging Initiative | Q4738819 |
| John Q. Trojanowski | Q6253636 | ||
| Piotr Lewczuk | Q58229544 | ||
| Leslie M. Shaw | Q106957202 | ||
| Holly D Soares | Q114270571 | ||
| Eric R Siemers | Q114336801 | ||
| Ronald C. Petersen | Q56839853 | ||
| Michael W. Weiner | Q56850515 | ||
| William J. Jagust | Q56863004 | ||
| Magdalena Korecka | Q57013132 | ||
| Kaj Blennow | Q28321550 | ||
| Arthur W. Toga | Q28516610 | ||
| Paul S. Aisen | Q30299891 | ||
| Clifford Jack | Q30505709 | ||
| P2093 | author name string | Adam Simon | |
| Christopher M Clark | |||
| Virginia M-Y Lee | |||
| William Z Potter | |||
| Robert Dean | |||
| Hugo Vandeerstichele | |||
| P2860 | cites work | Total and phosphorylated tau protein as biological markers of Alzheimer's disease | Q33624674 |
| Cerebrospinal fluid abnormalities and rate of decline in everyday function across the dementia spectrum: normal aging, mild cognitive impairment, and Alzheimer disease | Q33924646 | ||
| Cerebrospinal fluid and plasma biomarkers in Alzheimer disease | Q34098866 | ||
| Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics | Q36755348 | ||
| MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkers | Q37158181 | ||
| Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects | Q37227424 | ||
| Mapping correlations between ventricular expansion and CSF amyloid and tau biomarkers in 240 subjects with Alzheimer's disease, mild cognitive impairment and elderly controls | Q37227438 | ||
| Alzheimer's disease neuroimaging initiative: a one-year follow up study using tensor-based morphometry correlating degenerative rates, biomarkers and cognition | Q37228160 | ||
| MRI and CSF biomarkers in normal, MCI, and AD subjects: diagnostic discrimination and cognitive correlations | Q37273551 | ||
| MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change | Q37273569 | ||
| Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment | Q37313709 | ||
| Relationships between biomarkers in aging and dementia | Q37393992 | ||
| Use of Alzheimer disease biomarkers: potentially yes for clinical trials but not yet for clinical practice | Q42954747 | ||
| Mild cognitive impairment: Can FDG-PET predict who is to rapidly convert to Alzheimer's disease? | Q44411562 | ||
| Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study | Q44452244 | ||
| CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. | Q45923691 | ||
| Neuropathology of cognitively normal elderly | Q48125911 | ||
| Mixed brain pathologies account for most dementia cases in community-dwelling older persons | Q48136681 | ||
| Medial temporal lobe atrophy and memory dysfunction as predictors for dementia in subjects with mild cognitive impairment | Q48146954 | ||
| Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease | Q48266934 | ||
| Age, neuropathology, and dementia. | Q48597534 | ||
| MRI-derived entorhinal and hippocampal atrophy in incipient and very mild Alzheimer's disease. | Q48713862 | ||
| Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. | Q48820847 | ||
| Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals. | Q51125007 | ||
| Recent clinical-pathologic research on the causes of dementia in late life: update from the Honolulu-Asia Aging Study. | Q51923948 | ||
| Use of structural magnetic resonance imaging to predict who will get Alzheimer's disease. | Q52027757 | ||
| Use of cerebrospinal fluid biomarkers for diagnosis of incipient Alzheimer disease in patients with mild cognitive impairment. | Q53305918 | ||
| Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people | Q22253051 | ||
| Biological markers of amyloid beta-related mechanisms in Alzheimer's disease | Q24622136 | ||
| Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease | Q27860795 | ||
| Physical basis of cognitive alterations in alzheimer's disease: Synapse loss is the major correlate of cognitive impairment | Q29547294 | ||
| Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade | Q29614407 | ||
| Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria | Q29614408 | ||
| Mild cognitive impairment as a diagnostic entity | Q29619568 | ||
| HPLC-atmospheric pressure chemical ionization MS/MS for quantification of 15-F2t-isoprostane in human urine and plasma | Q33436499 | ||
| Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization | Q33601338 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Alzheimer's disease | Q11081 |
| neuroimaging | Q551875 | ||
| biomarker | Q864574 | ||
| Alzheimer's Disease Neuroimaging Initiative | Q4738819 | ||
| P304 | page(s) | 230-238 | |
| P577 | publication date | 2010-05-01 | |
| P1433 | published in | Alzheimer's and Dementia | Q15750965 |
| P1476 | title | Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects | |
| P478 | volume | 6 |
| Q30971403 | 2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception |
| Q64988752 | A 'Framingham-like' Algorithm for Predicting 4-Year Risk of Progression to Amnestic Mild Cognitive Impairment or Alzheimer's Disease Using Multidomain Information. |
| Q85845334 | A Dynamical Clustering Model of Brain Connectivity Inspired by the N -Body Problem |
| Q28547333 | A Subset of Cerebrospinal Fluid Proteins from a Multi-Analyte Panel Associated with Brain Atrophy, Disease Classification and Prediction in Alzheimer's Disease |
| Q33715736 | A commonly carried genetic variant in the delta opioid receptor gene, OPRD1, is associated with smaller regional brain volumes: replication in elderly and young populations |
| Q36933757 | A composite score for executive functioning, validated in Alzheimer's Disease Neuroimaging Initiative (ADNI) participants with baseline mild cognitive impairment |
| Q36813479 | A model for improving the treatment and care of Alzheimer's disease patients through interdisciplinary research |
| Q37710439 | A multinational study distinguishing Alzheimer's and healthy patients using cerebrospinal fluid tau/Aβ42 cutoff with concordance to amyloid positron emission tomography imaging |
| Q37600861 | A platform for discovery: The University of Pennsylvania Integrated Neurodegenerative Disease Biobank |
| Q38653383 | A user's guide for α-synuclein biomarker studies in biological fluids: Perianalytical considerations |
| Q39558416 | A versatile omnibus test for detecting mean and variance heterogeneity. |
| Q92702373 | APOE Promoter Polymorphism-219T/G is an Effect Modifier of the Influence of APOE ε4 on Alzheimer's Disease Risk in a Multiracial Sample |
| Q36259716 | APOE effect on Alzheimer's disease biomarkers in older adults with significant memory concern |
| Q37703128 | Age at injury is associated with the long-term cognitive outcome of traumatic brain injuries |
| Q64108437 | Age-related hearing loss accelerates cerebrospinal fluid tau levels and brain atrophy: a longitudinal study |
| Q28477836 | Alzheimer's disease and non-demented high pathology control nonagenarians: comparing and contrasting the biochemistry of cognitively successful aging |
| Q37180713 | Alzheimer's disease clinical and research update for health care practitioners |
| Q34236219 | Alzheimer's disease: The role for neurosurgery |
| Q39451611 | Amyloid Beta and Tau as Alzheimer's Disease Blood Biomarkers: Promise From New Technologies |
| Q36955963 | Amyloid-β Peptides and Tau Protein as Biomarkers in Cerebrospinal and Interstitial Fluid Following Traumatic Brain Injury: A Review of Experimental and Clinical Studies |
| Q33924292 | Anxiety is related to Alzheimer cerebrospinal fluid markers in subjects with mild cognitive impairment |
| Q34808510 | Apolipoprotein E, gender, and Alzheimer's disease: an overlooked, but potent and promising interaction |
| Q40032141 | Application of the IWG-2 Diagnostic Criteria for Alzheimer's Disease to the ADNI. |
| Q37027184 | Application of the National Institute on Aging-Alzheimer's Association AD criteria to ADNI |
| Q36675775 | Ascorbic acid, cognitive function, and Alzheimer's disease: a current review and future direction |
| Q37268405 | Association Between Anticholinergic Medication Use and Cognition, Brain Metabolism, and Brain Atrophy in Cognitively Normal Older Adults |
| Q91875401 | Association of Longitudinal Changes in Cerebrospinal Fluid Total Tau and Phosphorylated Tau 181 and Brain Atrophy With Disease Progression in Patients With Alzheimer Disease |
| Q34433766 | Association of cancer history with Alzheimer's disease onset and structural brain changes |
| Q38119019 | Atherosclerosis, biomarkers of atherosclerosis and Alzheimer's disease |
| Q37396195 | Basal forebrain degeneration precedes and predicts the cortical spread of Alzheimer's pathology. |
| Q34315258 | Biomarker discovery for Alzheimer's disease, frontotemporal lobar degeneration, and Parkinson's disease |
| Q34620948 | Biomarker progressions explain higher variability in stage-specific cognitive decline than baseline values in Alzheimer disease |
| Q35714382 | Biomarkers for predicting cognitive decline in those with normal cognition |
| Q38979999 | Biomarkers for the Early Detection and Progression of Alzheimer's Disease |
| Q27024518 | Biomarkers in Alzheimer's disease analysis by mass spectrometry-based proteomics |
| Q39413097 | Biomarkers in Neurodegenerative Diseases |
| Q38592041 | Biomarkers in Sporadic and Familial Alzheimer's Disease |
| Q33893515 | Biomarkers in frontotemporal lobar degenerations--progress and challenges |
| Q35030049 | Biomarkers of the dementia. |
| Q53213626 | Biomarkers: warning signs. |
| Q28259585 | Brain insulin resistance and deficiency as therapeutic targets in Alzheimer's disease |
| Q33745617 | Building a pipeline to discover and validate novel therapeutic targets and lead compounds for Alzheimer's disease |
| Q36851017 | CSF biomarker associations with change in hippocampal volume and precuneus thickness: implications for the Alzheimer's pathological cascade |
| Q36592268 | CSF complement 3 and factor H are staging biomarkers in Alzheimer's disease |
| Q35857246 | Can Genetic Analysis of Putative Blood Alzheimer's Disease Biomarkers Lead to Identification of Susceptibility Loci? |
| Q48941650 | Cerebrospinal Fluid proNGF: A Putative Biomarker for Early Alzheimer's Disease. |
| Q90118766 | Cerebrospinal fluid biomarkers and cognitive status in differential diagnosis of frontotemporal dementia and Alzheimer's disease |
| Q36626657 | Cerebrospinal fluid biomarkers for differentiation of frontotemporal lobar degeneration from Alzheimer's disease |
| Q89841162 | Cerebrospinal fluid ceruloplasmin levels predict cognitive decline and brain atrophy in people with underlying β-amyloid pathology |
| Q37948846 | Challenges in the development of companion diagnostics for neuropsychiatric disorders |
| Q64914406 | Characterizing heterogeneity in the progression of Alzheimer's disease using longitudinal clinical and neuroimaging biomarkers. |
| Q45944353 | Classifying MCI Subtypes in Community-Dwelling Elderly Using Cross-Sectional and Longitudinal MRI-Based Biomarkers. |
| Q98467183 | Clinical and biomarker trajectories in sporadic Alzheimer's disease: A longitudinal study |
| Q39820325 | Clinical trials of disease-modifying therapies for neurodegenerative diseases: the challenges and the future |
| Q40312806 | Combined Genome-Wide CSF Aβ-42's Associations and Simple Network Properties Highlight New Risk Factors for Alzheimer's Disease |
| Q36482533 | Comparison of cerebrospinal fluid levels of tau and Aβ 1-42 in Alzheimer disease and frontotemporal degeneration using 2 analytical platforms |
| Q30487243 | Computational genetics analysis of grey matter density in Alzheimer's disease |
| Q37487835 | Conflicting cerebrospinal fluid biomarkers and progression to dementia due to Alzheimer's disease |
| Q35997824 | Contributions of brain insulin resistance and deficiency in amyloid-related neurodegeneration in Alzheimer's disease |
| Q36606287 | Cross-View Neuroimage Pattern Analysis in Alzheimer's Disease Staging |
| Q36934163 | Detection of Alzheimer's disease at mild cognitive impairment and disease progression using autoantibodies as blood-based biomarkers |
| Q37189385 | Dissociable effects of Alzheimer disease and white matter hyperintensities on brain metabolism |
| Q35811894 | Drug development in pediatric psychiatry: current status, future trends |
| Q38341369 | ELISA in the multiplex era: potentials and pitfalls. |
| Q31109560 | Early role of vascular dysregulation on late-onset Alzheimer's disease based on multifactorial data-driven analysis |
| Q37675866 | Estrogen regulation of mitochondrial bioenergetics: implications for prevention of Alzheimer's disease |
| Q64991923 | Exercise prevents obesity-induced cognitive decline and white matter damage in mice. |
| Q35593903 | FASTKD2 is associated with memory and hippocampal structure in older adults |
| Q42147036 | FLOW-BASED NETWORK MEASURES OF BRAIN CONNECTIVITY IN ALZHEIMER'S DISEASE. |
| Q47874796 | Family history and TOMM40 '523 interactive associations with memory in middle-aged and Alzheimer's disease cohorts |
| Q37693146 | Fluid biomarkers for diagnosing dementia: rationale and the Canadian Consensus on Diagnosis and Treatment of Dementia recommendations for Canadian physicians |
| Q37273916 | Genetic interactions within inositol-related pathways are associated with longitudinal changes in ventricle size |
| Q29417147 | Genome-wide association study of CSF biomarkers Abeta1-42, t-tau, and p-tau181p in the ADNI cohort |
| Q34394932 | Genome-wide association study of CSF levels of 59 alzheimer's disease candidate proteins: significant associations with proteins involved in amyloid processing and inflammation |
| Q36064238 | Genome-wide association study of prolactin levels in blood plasma and cerebrospinal fluid |
| Q51065265 | Heart-type fatty acid binding protein and vascular endothelial growth factor: cerebrospinal fluid biomarker candidates for Alzheimer's disease. |
| Q35178436 | High Throughput ELISAs to Measure a Unique Glycan on Transferrin in Cerebrospinal Fluid: A Possible Extension toward Alzheimer's Disease Biomarker Development |
| Q28650395 | Imago Mundi, Imago AD, Imago ADNI |
| Q30667304 | In vivo imaging in NHP models of malaria: challenges, progress and outlooks |
| Q35175404 | Is hyperhomocysteinemia an Alzheimer's disease (AD) risk factor, an AD marker, or neither? |
| Q53337462 | Low dose, high dose, or no dose: better prescribing of cholinesterase inhibitors for Alzheimer's disease. |
| Q30540746 | MRI and cerebrospinal fluid biomarkers for predicting progression to Alzheimer's disease in patients with mild cognitive impairment: a diagnostic accuracy study |
| Q45077670 | Mapping longitudinal scientific progress, collaboration and impact of the Alzheimer's disease neuroimaging initiative |
| Q64814709 | Mass spectrometry: A platform for biomarker discovery and validation for Alzheimer's and Parkinson's diseases |
| Q51766023 | Measurements of auto-antibodies to α-synuclein in the serum and cerebral spinal fluids of patients with Parkinson's disease. |
| Q35846547 | Measuring Compounds in Exhaled Air to Detect Alzheimer's Disease and Parkinson's Disease |
| Q37669025 | MicroRNA in Alzheimer's disease: an exploratory study in brain, cerebrospinal fluid and plasma |
| Q26822601 | Mild cognitive impairment and its management in older people |
| Q38836004 | Molecular and cellular pathophysiology of preclinical Alzheimer's disease |
| Q36617517 | Neurodegenerative disease biomarkers: guideposts for disease prevention through early diagnosis and intervention |
| Q38430889 | Neuroimaging Feature Terminology: A Controlled Terminology for the Annotation of Brain Imaging Features |
| Q37639158 | Neuroimaging and other biomarkers for Alzheimer's disease: the changing landscape of early detection |
| Q33683377 | Neuropathologic heterogeneity does not impair florbetapir-positron emission tomography postmortem correlates |
| Q33881726 | New tools for the study of Alzheimer's disease: what are biomarkers and morphometric markers teaching us? |
| Q35698877 | Non-monotonic reorganization of brain networks with Alzheimer's disease progression |
| Q33813927 | Nutrients required for phospholipid synthesis are lower in blood and cerebrospinal fluid in mild cognitive impairment and Alzheimer's disease dementia |
| Q41871950 | OPTIMIZING BRAIN CONNECTIVITY NETWORKS FOR DISEASE CLASSIFICATION USING EPIC. |
| Q36221014 | OPTIMIZING DIAGNOSIS AND MANANGEMENT IN MILD-TO-MODERATE ALZHEIMER'S DISEASE. |
| Q33705614 | Parkinson disease: PD biomarkers-use of α-synuclein reaches new levels |
| Q38344088 | Paths to Alzheimer's disease prevention: from modifiable risk factors to biomarker enrichment strategies |
| Q37897692 | Perfusion SPECT and FDG-PET. |
| Q38101555 | Perspectives on episodic-like and episodic memory |
| Q41097447 | Plasma Levels of Aβ42 and Tau Identified Probable Alzheimer's Dementia: Findings in Two Cohorts |
| Q34427001 | Plasma based markers of [11C] PiB-PET brain amyloid burden |
| Q35844316 | Plasma biomarkers of depressive symptoms in older adults |
| Q36183810 | Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease |
| Q36713678 | Postmortem Pittsburgh Compound B (PiB) binding increases with Alzheimer's disease progression. |
| Q33979812 | Preclinical non-human models to combat dementia |
| Q47863932 | Prediction of Free and Cued Selective Reminding Test Performance Using Volumetric and Amyloid-Based Biomarkers of Alzheimer's Disease |
| Q35070237 | Preoperative cognitive assessment of the elderly surgical patient: a call for action |
| Q35218413 | Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI. |
| Q37800101 | Quantification of α-synuclein in cerebrospinal fluid as a biomarker candidate: review of the literature and considerations for future studies |
| Q36702235 | Quantitative appraisal of ventricular cerebrospinal fluid biomarkers in neuropathologically diagnosed Parkinson's disease cases lacking Alzheimer's disease pathology |
| Q33729033 | Quantitative structural MRI for early detection of Alzheimer's disease |
| Q36451170 | Random forest-based similarity measures for multi-modal classification of Alzheimer's disease |
| Q34372593 | Rates of decline in Alzheimer disease decrease with age. |
| Q48506785 | Ratio of β-amyloid protein (Aβ) and Tau predicts the postoperative cognitive dysfunction on patients undergoing total hip/knee replacement surgery. |
| Q48434259 | Reducing amyloid-related Alzheimer's disease pathogenesis by a small molecule targeting filamin A. |
| Q38435318 | Regional neuronal network failure and cognition in late-onset sporadic Alzheimer disease. |
| Q36435826 | Relative contributions of biomarkers in Alzheimer's disease |
| Q35542811 | Role of cerebrospinal fluid and plasma biomarkers in the diagnosis of neurodegenerative disorders and mild cognitive impairment |
| Q90378072 | Serum Vitamin B12, and Related MTRR and Cubilin Genotypes, Predict Neural Outcomes across the AD Spectrum |
| Q26830740 | Shift in brain metabolism in late onset Alzheimer's disease: implications for biomarkers and therapeutic interventions |
| Q101224590 | Single-molecule studies of amyloid proteins: from biophysical properties to diagnostic perspectives |
| Q41841109 | Tau is reduced in AD plasma and validation of employed ELISA methods |
| Q35339326 | The "Alzheimer's disease signature": potential perspectives for novel biomarkers. |
| Q36914046 | The ADNI Publication Policy: commensurate recognition of critical contributors who are not authors |
| Q37451440 | The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans |
| Q27006831 | The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception |
| Q34065449 | The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. |
| Q28749585 | The Alzheimer's disease neuroimaging initiative: progress report and future plans |
| Q37077593 | The C677T variant in MTHFR modulates associations between blood-based and cerebrospinal fluid biomarkers of neurodegeneration |
| Q38881076 | The Effect of Propofol Versus Isoflurane Anesthesia on Human Cerebrospinal Fluid Markers of Alzheimer's Disease: Results of a Randomized Trial |
| Q28271237 | The MAPT H1 haplotype is associated with tangle-predominant dementia |
| Q47897788 | The Relationship of Brain Amyloid Load and APOE Status to Regional Cortical Thinning and Cognition in the ADNI Cohort |
| Q34296479 | The diagnosis and evaluation of dementia and mild cognitive impairment with emphasis on SPECT perfusion neuroimaging |
| Q35870359 | The many faces of tau |
| Q36729508 | The role of apolipoprotein E (APOE) genotype in early mild cognitive impairment (E-MCI). |
| Q28088291 | The use of cerebrospinal fluid and neuropathologic studies in neuropsychiatry practice and research |
| Q37268375 | Traumatic brain injury and age at onset of cognitive impairment in older adults |
| Q47118607 | Type 2 diabetes mellitus and cerebrospinal fluid Alzheimer's disease biomarker amyloid β1-42 in Alzheimer's Disease Neuroimaging Initiative participants |
| Q42373062 | Type 2 diabetes mellitus is associated with brain atrophy and hypometabolism in the ADNI cohort |
| Q37195596 | Unbiased comparison of sample size estimates from longitudinal structural measures in ADNI. |
| Q37203023 | Unbiased tensor-based morphometry: improved robustness and sample size estimates for Alzheimer's disease clinical trials |
| Q37980501 | Use of cerebrospinal fluid biomarkers in clinical trials for schizophrenia and depression |
| Q47860105 | Vaccination strategies in tauopathies and synucleinopathies |
| Q50788584 | Value of neuropsychological tests, neuroimaging, and biomarkers for diagnosing Alzheimer's disease in younger and older age cohorts. |
| Q36064283 | Variants in ACPP are associated with cerebrospinal fluid Prostatic Acid Phosphatase levels |
| Q36064313 | Variants in CCL16 are associated with blood plasma and cerebrospinal fluid CCL16 protein levels |
| Q37820120 | α-Synuclein and DJ-1 as potential biological fluid biomarkers for Parkinson's Disease |
Search more.